A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
NCT ID: NCT07241104
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
31 participants
INTERVENTIONAL
2025-12-01
2027-11-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The SAD part of the study will assess the single doses of AZD4063 across 3 cohorts. It will consist of:
* A screening period
* A treatment period: The participants will receive a single dose of AZD4063 by subcutaneous (SC) injection
* A follow-up period
The MAD part of the study will initiate on receiving the data from SAD cohort with available safety, PK and pharmacodynamics (PD) data from all cohorts. This part of the study will consist of:
* A screening period
* A treatment period: The participants will receive multiple doses of AZD4063 by SC injection
* A follow-up period
Optional cohorts may be added based on emerging safety, PK and PD data of the SAD and MAD cohorts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 (SAD): Dose 1 of AZD4063
Participants will receive Dose 1 of AZD4063 via SC injection in Cohort 1 of SAD.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Cohort 2 (SAD): Dose 2 of AZD4063
Participants will receive Dose 2 of AZD4063 via SC injection in Cohort 2 of SAD.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Cohort 3 (SAD): Dose 3 of AZD4063
Participants will receive Dose 3 of AZD4063 via SC injection in Cohort 3 of SAD.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Cohort 1 (MAD): Dose 4 of AZD4063
Participants will receive Dose 4 of AZD4063 via SC injection in Cohort 1 of MAD.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Cohort 2 (MAD): Dose 5 of AZD4063
Participants will receive Dose 5 of AZD4063 via SC injection in Cohort 2 of MAD.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Cohort 3 (MAD): Dose 6 of AZD4063
Participants will receive Dose 6 of AZD4063 via SC injection in Cohort 3 of MAD.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Optional Cohort 1 (SAD): Dose 7 of AZD4063
Participants will receive Dose 7 of AZD4063 via SC injection in the optional cohort of the study. This additional cohort will be added depending on the findings.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Optional Cohort 2 (SAD): Dose 8 of AZD4063
Participants will receive Dose 8 of AZD4063 via SC injection in the optional cohort of the study. This additional cohort will be added depending on the findings.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Optional Cohort 1 (MAD): Dose 9 of AZD4063
Participants will receive Dose 9 of AZD4063 via SC injection in the optional cohort of the study. This additional cohort will be added depending on the findings.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Optional Cohort 2 (MAD): Dose 10 of AZD4063
Participants will receive Dose 10 of AZD4063 via SC injection in the optional cohort of the study. This additional cohort will be added depending on the findings.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with pre-existing positive screening for R14 del PLN mutation
* Participants with screening Left ventricular eject fraction ≤ 45% as assessed by echocardiography
* Participants with New York Heart Association (NYHA) function class I-III
* Participants on stable medical therapy for at least 6 weeks prior to Screening and during the Screening period, with no significant improvement in heart failure
* Participants with implantable cardioverter-defibrillator (ICD) or Cardiac resynchronization therapy device (CRT-D)
* Participants with Body mass index (BMI) within the range 18-35 kg/m2
* Females of childbearing potential must not be lactating, and if heterosexually active must agree to use an approved method of highly effective contraception
* All females must have a negative pregnancy test at the Screening Visit.
Exclusion Criteria
* Known to have tested positive for Human immunodeficiency virus (HIV)
* Any known genetic mutation associated with hereditary electrical or structural disease
* Congenital long QT syndrome
* QTcF \< 350 ms
* Known Short QT syndrome (SQTS) or family history of SQTS
* Catecholaminergic polymorphic ventricular tachycardia (CPVT as calcium ion channelopathy) and recent hospitalization for heart failure or significant ventricular arrhythmia within 3 months
* Participants with sustained ventricular arrhythmia requiring treatment and considered clinically not stable by the Investigator
* History of subendocardial Late Gadolinium Enhancement (LGE) suggestive of previous myocardial infarction and/or significant coronary artery disease (50% \> stenosis in one major epicardial coronary artery or need for previous percutaneous coronary intervention or coronary artery bypass grafting)
* Routinely scheduled outpatient intravenous infusions for heart failure
* Uncontrolled hypertension
* Significant primary valvular disease
* Congenital heart disease
* Left ventricular wall thickness of \> 13 mm or with any relative with hypertrophic cardiomyopathy (HCM)
* Recent acute presentation of myocarditis
* Restrictive or peripartum cardiomyopathy; infiltrative disorders (sarcoidosis)
* Alcohol consumption in excess
* Any laboratory values with the following deviations:
1. Alanine Transaminase \>2 upper normal limit (ULN)
2. Aspartate Transaminase \>2 ULN
3. Total bilirubin \> 2 x ULN
4. Estimated GFR \< 30 mL/min/1.73 m2
5. Hemoglobin \<10g/dL
* Any vital sign values with the following deviations at Screening
1. Systolic blood pressure \> 160 mmHg
2. Diastolic blood pressure \> 100 mmHg
3. Pulse rate \> 100 beats per minute
* Toxin exposure, systemic disease known to cause Dilated Cardiomyopathy (DCM)
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity
* Any history of cardiotoxic drug exposure with documented cardiomyopathy
* Noncardiac condition that limits expected lifespan to less than 1 year
* Participation in another clinical study with a study intervention administered in the last 3 months
* Participants with a known hypersensitivity to AZD4063
* Participants who are part of a gene therapy trial
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Amsterdam, , Netherlands
Research Site
Groningen, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Utrecht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
AstraZeneca Clinical Study Information Center
Role: CONTACT
Phone: 1-877-240-9479
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8340C00001
Identifier Type: -
Identifier Source: org_study_id